# US 2021/0369830 A1 · Clostridium difficile antigens

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0369830 A1
- Document ID: US20210369830A1
- Status: Published application
- Kind: A1
- Application number: 17/224,404
- Filed: 2021-04-07
- Published: 2021-12-02
- Earliest claimed: 2010-10-05
- Assignees: Secretary of State for Health and Social Care; MicroPharm Limited
- Applicants: Secretary of State for Health and Social Care; MicroPharm Limited
- Inventors: Clifford Shone; April Roberts; Helen Ahern; Michael Maynard-Smith; John Landon
- Web page: https://patentgrep.com/patent/US20210369830A1

## CPC

- A61K 39/08: Clostridium, e.g. Clostridium tetani
- A61K 38/164: {from bacteria}
- A61K 39/40: bacterial
- A61P 31/04: Antibacterial agents
- C07K 14/33: from Clostridium (G)
- C07K 16/1282: Clostridium (G)
- A61K 2039/505: {comprising antibodies}
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C07K 2319/00: Fusion polypeptide
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

The present application relates to recombinant Clostridium difficile antigens based on a fusion protein that consists of or comprises a first amino acid sequence and a second amino acid sequence, wherein: a) the first amino acid sequence is provided by an amino acid sequence that has at least 80% sequence identity with an amino acid sequence consisting of residues 1500-1850 of a C. difficile Toxin A sequence or residues 1500-1851 of a C. difficile Toxin B sequence; and b) the second amino acid sequence is provided by an amino acid sequence that has at least 80% sequence identity with an amino acid sequence consisting of a long repeat unit located within amino acid residues 1851-2710 of a C. difficile Toxin A sequence or within amino acid residues 1852-2366 of a C. difficile Toxin B sequence; though with the proviso that the fusion protein is not a polypeptide comprising amino acid residues 543-2710 of a C. difficile Toxin A and with the proviso that the fusion protein is not a polypeptide comprising amino acid residues 543-2366 of a C. difficile Toxin B. Also provided is the use of said antigens for the prevention/treatment/suppression of Clostridium difficile infection (CDI), together with methods for generating said antigens, methods for generating antibodies that bind to said antigens, and the use of said antibodies for the prevention/treatment/suppression of CDI.

## Claims

### Claim 1

A method for preventing, treating, or suppressing Clostridium difficile (C. difficile) infection in a human, said method comprising administering to said human a therapeutically effective amount of polyclonal antibodies, wherein said polyclonal antibodies bind to a C. difficile Toxin B, do not substantially bind to the effector domain and/or to the cysteine protease domain of C. difficile Toxin B, and can elicit a C difficile Toxin B-neutralizing immune response,
wherein said polyclonal antibodies are obtained by immunizing a sheep with a protein comprising:
a) an amino acid sequence having at least 90% sequence identity with amino acid residues 767-2366 of a C. difficile Toxin B sequence; or
b) an amino acid sequence having at least 90% sequence identity with amino acid residues 1145-2366 of a C. difficile Toxin B sequence;
to induce production of polyclonal antibodies specific for C. difficile Toxin B, with the proviso that the protein does not comprise amino acid residues 543-2366 of the C. difficile Toxin B; and
wherein said C. difficile Toxin B are sequence is the amino acid sequence of SEQ ID NO: 2 or the amino acid sequence of SEQ ID NO: 4.

### Claim at position 2

2-3. (canceled)

### Claim 4 (depends on 1)

The method according to claim 1, wherein the polyclonal antibodies are isolated.

### Claim 5 (depends on 4)

The method according to claim 4, wherein the polyclonal antibodies are isolated by affinity purification.

### Claim 6

(canceled)

### Claim 7 (depends on 1)

The method according to claim 1, wherein said polyclonal antibodies are administered in combination with one or more additional antibodies, wherein the one or more additional antibody is an antibody that binds to a C. difficile non-Toxin antigen, and/or is an antibody that binds to a whole cell C. difficile bacterium.

### Claim 8 (depends on 7)

The method according to claim 7, wherein the one or more antibody is selected from:
a) an antibody that binds to antigen from a bacterium that causes nosocomial infection, and/or
b) an antibody that binds to a whole cell bacterium that causes nosocomial infection.

### Claim 9 (depends on 1)

The method according to claim 1, wherein the polyclonal antibodies are combined with one or more antibiotic.

### Claim 10 (depends on 9)

The method according to claim 9, wherein the antibiotic is an antibiotic effective against a bacterium that causes a nosocomial infection.

### Claim 11 (depends on 7)

The method according to claim 7, wherein the one or more antibody is combined with one or more antibiotic.

### Claim 12 (depends on 11)

The method according to claim 11, wherein the antibiotic is an antibiotic effective against a bacterium that causes nosocomial infection.

### Claim 13

A method for treating a C. difficile infection in a patient comprising:
using an in vitro immunoassay method to confirm the presence or absence of a C. difficile infection in a patient sample, wherein said immunoassay comprises the steps of:
combining the patient sample with polyclonal antibodies for a time sufficient for antibody binding with C. difficile Toxin B present in the patient sample;
detecting the presence of antibody binding with C. difficile Toxin B in the patient sample;
wherein the presence of a C. difficile infection is confirmed by detecting the binding of said polyclonal antibodies to a C. difficile Toxin B present in said patient sample,
wherein failure to detect the binding of said polyclonal antibodies to a C. difficile Toxin B present in said patient sample confirms the absence of a C. difficile infection, and
wherein the said patient confirmed as having C. difficile in said patient sample is administered a therapeutically effective amount of the polyclonal antibodies;
wherein said polyclonal antibodies bind to a C. difficile Toxin B, do not substantially bind to the effector domain and/or to the cysteine protease domain of C. difficile Toxin B, and can elicit a C. difficile Toxin B-neutralizing immune response,
wherein said polyclonal antibodies are obtained by immunizing a sheep with a protein comprising:
a) an amino acid sequence having at least 90% sequence identity with amino acid residues 767-2366 of a C. difficile Toxin B sequence; or
b) an amino acid sequence having at least 90% sequence identity with amino acid residues 1145-2366 of a C. difficile Toxin B sequence;
to induce production of polyclonal antibodies specific for C. difficile Toxin B; with the proviso that the protein does not comprise amino acid residues 543-2366 of the C. difficile Toxin B; and
wherein said C. difficile Toxin B sequence is the amino acid sequence of SEQ ID NO: 2 or the amino acid sequence of SEQ ID NO: 4.

### Claim 14 (depends on 1)

The method according to claim 1, wherein said polyclonal antibodies are administered in combination with polyclonal antibodies that bind to C. difficile Toxin A.

### Claim 15 (depends on 14)

The method according to claim 14, wherein said polyclonal antibodies that bind to C. difficile Toxin A are sheep polyclonal antibodies that bind to C. difficile Toxin A.

### Claim 16 (depends on 15)

The method according to claim 15, wherein said sheep polyclonal antibodies that bind to C. difficile Toxin A are obtained by immunizing sheep with a protein comprising:
a) an amino acid sequence having at least 90% sequence identity with amino acid residues 770-2710 of a C. difficile Toxin A sequence;
b) an amino acid sequence having at least 90% sequence identity with amino acid residues 770-2389 of a C. difficile Toxin A sequence; or
c) an amino acid sequence having at least 90% sequence identity with amino acid residues 1850-2710 of a C. difficile Toxin A sequence;
to induce production of polyclonal antibodies specific for C. difficile Toxin A; and
wherein said C. difficile Toxin A sequence is the amino acid sequence of SEQ ID NO: 1 or the amino acid sequence of SEQ ID NO: 3.

### Claim 17 (depends on 13)

The method according to claim 13, wherein the polyclonal antibodies are isolated.

### Claim 18 (depends on 17)

The method according to claim 17, wherein the polyclonal antibodies are isolated by affinity purification.

### Claim 19 (depends on 13)

The method according to claim 13, wherein said polyclonal antibodies are administered in combination with one or more additional antibodies, wherein the one or more additional antibodies is an antibody that binds to a C. difficile non-Toxin, and/or is an antibody that binds to a whole cell C. difficile bacterium.

### Claim 20 (depends on 13)

The method according to claim 13, wherein said polyclonal antibodies are combined with one or more antibiotic.

### Claim 21 (depends on 13)

The method according to claim 13, wherein said polyclonal antibodies are administered in combination with polyclonal antibodies that bind to C. difficile Toxin A.

### Claim 22 (depends on 21)

The method according to claim 21, wherein said polyclonal antibodies that bind to C. difficile Toxin A are sheep polyclonal antibodies that bind to C. difficile Toxin A.

### Claim 23 (depends on 22)

The method according to claim 22, wherein said sheep polyclonal antibodies that bind to C. difficile Toxin A are obtained by immunizing sheep with a protein comprising:
a) an amino acid sequence having at least 90% sequence identity with amino acid residues 770-2710 of a C. difficile Toxin A sequence;
b) an amino acid sequence having at least 90% sequence identity with amino acid residues 770-2389 of a C. difficile Toxin A sequence; or
c) an amino acid sequence having at least 90% sequence identity with amino acid residues 1850-2710 of a C. difficile Toxin A sequence;
to induce production of polyclonal antibodies specific for C. difficile Toxin A; and
wherein said C. difficile Toxin A sequence is the amino acid sequence of SEQ ID NO: 3.
